Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:
* Diffuse Large B-Cell Lymphoma
* Burkitt Lymphoma
* High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)
* Primary mediastinal B-cell lymphoma (PMBL)
* CD20+ B-lymphoblastic lymphoma
* Follicular lymphoma, Grade III
* Karnofsky ≥ 60% for patients \> 16 years of age and
* Lansky ≥ 60 for patients ≤ 16 years of age.
* Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.
* Patients may not have received prior therapy with obinutuzumab (GA101)
* Radiation Therapy (XRT): Date of receiving prior XRT must be \> 2 weeks for local palliative XRT (small port); \> 6 months must have elapsed if prior craniospinal XRT or if \> 50% radiation of pelvis; \> 6 weeks must have elapsed if other substantial bone marrow radiation.
* Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.
* Adequate organ function.
You may not be if
Patients with newly diagnosed, previously untreated B-NHL.
Known congenital or acquired immune deficiency.
Prior solid organ transplantation.
Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies
